Geller Advisors LLC Gilead Sciences, Inc. Transaction History

Geller Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $103,310 - $117,156	-1,410 Reduced 34.71%	2,652 $214,000
Q3 2023 Nov 13, 2023	BUY	$73.94 - $80.67 $300,344 - $327,681	4,062 New	4,062 $304,000
Q1 2022 May 13, 2022	SELL	$57.92 - $72.58 $192,989 - $241,836	-3,332 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$64.88 - $73.64 $129 - $147	-2 Reduced 0.06%	3,332 $242,000
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $5,753 - $6,207	-85 Reduced 2.49%	3,334 $233,000
Q2 2021 Aug 09, 2021	BUY	$63.47 - $69.35 $698 - $762	11 Added 0.32%	3,419 $235,000
Q1 2021 May 10, 2021	BUY	$60.0 - $68.46 $69,000 - $78,729	1,150 Added 50.93%	3,408 $220,000
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $127,915 - $145,753	2,258 New	2,258 $209,000
Q3 2020 Nov 13, 2020	SELL	$62.1 - $78.08 $169,408 - $213,002	-2,728 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $197,343 - $229,152	2,728 New	2,728 $210,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Geller Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Geller Advisors LLC with notifications on news.